PBPierre Bougnères

Pierre Bougnères

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pierre Bougnères has a total of 256 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Enigma of Finnish and Sardinian Type 1 Diabetes Incidence: Where Population History Meets Genetics

    by Pierre Bougnères

    Finland and Sardinia have very high incidences of autoimmune type 1 diabetes (T1D), particularly in children, far exceeding those of other European countries—an enigma that has persisted for some forty years. Genetics has so far had only the established T1D-predisposing variants to work with: HLA, INS, and the roughly 80 GWAS loci. But the allele frequencies of these variants, comparable to those of other European populations, could not credit genetics with any particular role in the super-incidence. Notably, on published haplotype frequencies, HLA class II would place Sardinian incidence below the Finnish, whereas it stands some forty per cent above it, and no published comparison of class II frequencies across European populations accounts for the incidence gradient either. This is deeply frustrating, since the two populations have a highly distinctive history, making them uniquely isolated genetic outliers at the margins of Europe. In 2017, a seminal paper changed the picture by establishing the omnigenic model of human quantitative traits, which we apply here to T1D endotypes. This model rests on thousands, even tens of thousands, of rare, mostly non-coding and regulatory variants in the nuclear genome, each with a vanishingly small predisposing effect, invisible to T1D GWAS. Recently, this thinking has been extended by the stratagenic model, in which numerous rare variants act across diverse biological pathways such as those that compose T1D pathophysiology. Imagining how the history of the two populations could have produced rare, pathway-stratified genomic variants offers a plausible explanation for the super-incidence. Because the founder event itself displaces allele frequencies without direction, what founder history alone predicts is not high incidence but wide dispersion of incidence—Sardinia and Finland above the continental populations, Iceland below. Where prolonged selection is superimposed upon the founding draw, as malaria was in Sardinia and perhaps the famine in Finland, a direction can be added to that dispersion. We present and attempt to justify this hypothesis, state the observations that would refute it, and discuss the causal role of environment, which is a subject that has driven much epidemiological research in both Finland and Sardinia.

  • Open Access

    Brain Ketone Bodies in Health, Evolution and Disease

    by Pierre Bougnères

    Ketone bodies (KBs) are the only energy substrates oxidized by the brain, whose concentration in the circulation can greatly increase when a physiological situation requires it. For example, when an adult human fasts for two days, circulating KBs rise twenty-fold from ~0.1 to ~2 mM. As a fuel, KBs provide the brain with acetyl-CoA that produces ATP or glutamate, notably in certain brain regions. Remarkably, KBs activate the expression of their own cerebral transporters and KB-utilizing enzymes so that circulating levels determine cerebral utilization of KBs. Throughout evolution, the energetic role of KBs has been crucial for the metabolic homeostasis of humans endowed with a large brain and facing unpredictable periods of food shortage. Paradoxically, the brain of modern, regularly fed humans whose ordinary blood KBs are ~0.1 mM, has access to much fewer circulating sources of energy than that of their distant ancestors. KBs can modify certain proteins post-translationally, for example, histones through lysine-butyrylation. KBs could act as short- or long-term epigenetic messengers. These properties of KBs might allow a fetus to directly sense maternal starvation and adapt their cerebral metabolism to this situation, possibly preparing for nutritional constraints in extra-uterine life. KB transcriptional and epigenetic properties could also enable the postnatal organism to retain a molecular memory of its own starvation episodes. No other energy substrate, such as glucose or lactate, has such capacities. Medicine turned its attention to KBs a century ago. Indeed, KBs are the only energy substrates whose circulating levels can be increased, and nutritional interventions can alter them under free-living conditions. This property opens broad prospects for ketogenic diets (KDs) to prevent or rescue neurodegenerative diseases characterized by glucose hypometabolism, notably Alzheimer’s disease (AD). However, KDs have not yet found real medical applications, for reasons that are discussed.


  • Open Access

    Gene Therapy in Crohn’s Disease: Current Preclinical Challenges and Future Translational Avenues

    by Solafah Abdalla, Antoine Brouquet, Romina Aron-Badin, Pierre Bougnères

    Crohn’s disease (CD) remains a highly complex disorder, and the progress of preclinical gene therapy for CD has been constrained by several significant challenges. These include the identification of optimal therapeutic gene targets, the difficulty of targeting therapy-resistant cells within a chronic inflammatory microenvironment, particularly in the enteric nervous system (ENS), and the lack of robust animal models that faithfully recapitulate human pathology, as classical models largely rely on toxin-induced colitis. This review synthesizes major preclinical studies on gene therapy for CD and related inflammatory bowel diseases (IBD). We critically assess the rationale and biodistribution data for different vector platforms, considering vector type, promoter, and route of administration, in the ileum and colon of both rodent and non-human primate models. Special attention is given to strategies targeting the ENS. Finally, we explore the putative therapeutic aims of these approaches, including direct attenuation of intestinal inflammation and prevention of postoperative recurrence of CD via local intraoperative gene delivery. Although most data derive from chemical colitis models, this review establishes a foundational framework to inform translational research in gene therapy for CD and other IBDs.


  • Open Access

    A first step in the gene therapy of tubulin glutamylation disorders

    by Pierre Bougnères

  • Open Access

    Gene Therapy of Adrenomyeloneuropathy: Challenges, Target Cells, and Prospectives

    by Pierre Bougnères, Catherine Le Stunff, Romina Aron Badin

    Gene replacement using adeno-associated viral (AAV) vectors has become a major therapeutic avenue for neurodegenerative diseases (NDD). In single-gene diseases with loss-of-function mutations, the objective of gene therapy is to express therapeutic transgenes abundantly in cell populations that are implicated in the pathological phenotype. X-ALD is one of these orphan diseases. It is caused by ABCD1 gene mutations and its main clinical form is adreno-myelo-neuropathy (AMN), a disabling spinal cord axonopathy starting in middle-aged adults. Unfortunately, the main cell types involved are yet poorly identified, complicating the choice of cells to be targeted by AAV vectors. Pioneering gene therapy studies were performed in the Abcd1-/y mouse model of AMN with AAV9 capsids carrying the ABCD1 gene. These studies tested ubiquitous or cell-specific promoters, various routes of vector injection, and different ages at intervention to either prevent or reverse the disease. The expression of one of these vectors was studied in the spinal cord of a healthy primate. In summary, gene therapy has made promising progress in the Abcd1-/y mouse model, inaugurating gene replacement strategies in AMN patients. Because X-ALD is screened neonatally in a growing number of countries, gene therapy might be applied in the future to patients before they become overtly symptomatic.


  • Open Access

    Revisiting the Pathogenesis of X-Linked Adrenoleukodystrophy

    by Pierre Bougnères, Catherine Le Stunff

    Background: X-ALD is a white matter (WM) disease caused by mutations in the ABCD1 gene encoding the transporter of very-long-chain fatty acids (VLCFAs) into peroxisomes. Strikingly, the same ABCD1 mutation causes either devastating brain inflammatory demyelination during childhood or, more often, progressive spinal cord axonopathy starting in middle-aged adults. The accumulation of undegraded VLCFA in glial cell membranes and myelin has long been thought to be the central mechanism of X-ALD. Methods: This review discusses studies in mouse and drosophila models that have modified our views of X-ALD pathogenesis. Results: In the Abcd1 knockout (KO) mouse that mimics the spinal cord disease, the late manifestations of axonopathy are rapidly reversed by ABCD1 gene transfer into spinal cord oligodendrocytes (OLs). In a peroxin-5 KO mouse model, the selective impairment of peroxisomal biogenesis in OLs achieves an almost perfect phenocopy of cerebral ALD. A drosophila knockout model revealed that VLCFA accumulation in glial myelinating cells causes the production of a toxic lipid able to poison axons and activate inflammatory cells. Other mouse models showed the critical role of OLs in providing energy substrates to axons. In addition, studies on microglial changing substates have improved our understanding of neuroinflammation. Conclusions: Animal models supporting a primary role of OLs and axonal pathology and a secondary role of microglia allow us to revisit of X-ALD mechanisms. Beyond ABCD1 mutations, pathogenesis depends on unidentified contributors, such as genetic background, cell-specific epigenomics, potential environmental triggers, and stochasticity of crosstalk between multiple cell types among billions of glial cells and neurons.


  • Open Access

    CpG methylation changes associated with hyperglycemia in type 1 diabetes occur at angiogenic glomerular and retinal gene loci

    by Xiaojian Shao, Sophie Le Fur, Warren Cheung, Marie-Pierre Belot, Kevin Perge, Natacha Bouhours-Nouet, Candace Bensignor, Lucie Levaillant, Bing Ge, Tony Kwan, et al.

    Chronic hyperglycemia is a major risk factor for glomerular or retinal microangiopathy and cardiovascular complications of type 1 diabetes (T1D). At the interface of genetics and environment, dynamic epigenetic changes associated with hyperglycemia may unravel some of the mechanisms contributing to these T1D complications. In this study, blood samples were collected from 112 young patients at T1D diagnosis and 3 years later in average. Whole genome-wide bisulfite sequencing was used to measure blood DNA methylation changes of about 28 million CpGs at single base resolution over this time. Chronic hyperglycemia was estimated every 3–4 months by HbA1c measurement. Linear regressions with adjustment to age, sex, treatment duration, blood proportions and batch effects were employed to characterize the relationships between the dynamic changes of DNA methylation and average HbA1c levels. We identified that longitudinal DNA methylation changes at 815 CpGs (with suggestive p-value threshold of 1e-4) were associated with average HbA1c. Most of them (> 98%) were located outside of the promoter regions and were enriched in CpG island shores and multiple immune cell type specific accessible chromatin regions. Among the 36 more strongly associated loci (p-value < 5e-6), 16 were harbouring genes or non-coding sequences involved in angiogenesis regulation, glomerular and retinal vascularization or development, or coronary disease. Our findings support the identification of new genomic sites where CpG methylation associated with hyperglycemia may contribute to long-term complications of T1D, shedding light on potential mechanisms for further exploration.


  • Intracisternal AAV9-MAG- hABCD1 Vector Reverses Motor Deficits in Adult Adrenomyeloneuropathy Mice

    by Yasemin Özgür Günes, Catherine Le Stunff, Pierre Bougnères

    Worldwide, thousands of male patients who carry ATP Binding Cassette Subfamily D Member 1 ( ABCD1 ) mutations develop adrenomyeloneuropathy (AMN) in mid-adulthood, a debilitating axonopathy of the spinal cord. Today AAV gene therapy brings the most hope for this orphan disease. We previously reported that an AAV9-MAG- hABCD1 vector injected intravenously in the neonatal period prevented the disease in 2-year-old Abcd1−/− mice, the AMN mouse model. In the current study, the same vector was injected intracisternally at 18 months of age, when about half of Abcd1−/− mice start losing balance and motricity. As soon as 1–3 months after vector injection, motor tests have evolved differently in treated and untreated (UT) mice. Six months after vector, treated mice ( n = 24) had near-normal motor performances, whereas neurological state had deteriorated in UT mice ( n = 34). In five white matter regions of the cervical spinal cord, hABCD1 expression at 24 months of age was present in 22% (18–27) of oligodendrocytes (OLs) and 22% (17–26) of astrocytes and not detected in neurons or microglia. Abundant hABCD1 expression was also observed in OLs and astrocytes in the cerebellum and brainstem and, to a lesser level, in the lower spinal cord, not in the dorsal root ganglia or brain cortex. In conclusion, the effect of the AAV9-MAG- hABCD1 vector at an early symptomatic stage of the Abcd1−/− mouse model paves a new oligotropic way for the gene therapy of AMN.


  • Open Access

    Burden of Treatment in Children and Adolescents With Type 1 Diabetes Evaluated by Focus Groups

    by Sophie Le Fur, Iva Gueorguieva, Kevin Perge, Fatiha Guémazi, Nathalie Frament, Natacha Bouhours-Nouet, Berthe Razafimahefa, Pascale Trioche-Eberschweiler, Ramona Nicolescu, Patricia Pigeon-Kherchiche, et al.

    Objective: Taking into account the burden of treatment (BOT) should favor psychological fulfillment and adherence of young patients to treatment, which largely determines the quality of type 1 diabetes (T1D) control. To identify BOT components, the Ariane study carried out a focus group survey among 84 children and adolescents with T1D aged 12.6 ± 3.7 years. Research Design and Methods: Focus groups were organized in 10 pediatric diabetes centers, a qualitative research method that brings together a small group of patients to express their perception of treatment and answer questions in a moderated nonmedical setting. Results: A total of 3640 verbatim voicing children’s concerns were recorded, transcribed, and analyzed by five working groups composed of pediatric diabetologists, specialized nurses, adults with childhood‐onset T1D, and two groups from the civil society. Each group studied the verbatim separately to extract 24 main concerns summarizing BOT. These concerns fell into two distinct categories: concerns about physical, material, and care organization ( N = 15) or psychological concerns ( N = 9). A BOT score summed the number of concerns of each patient. The mean BOT score was 7.4 ± 3.3 (range 1–18). Gender had a prominent influence on concerns ( p = 0.002). Conclusions: The identification of common concerns expressed through focus groups provides a new tool for estimation of BOT in childhood T1D.

  • Open Access

    Oligodendrocytes, the Forgotten Target of Gene Therapy

    by Yasemin Ozgür-Gunes, Catherine Le Stunff, Pierre Bougnères

    If the billions of oligodendrocytes (OLs) populating the central nervous system (CNS) of patients could express their feelings, they would undoubtedly tell gene therapists about their frustration with the other neural cell populations, neurons, microglia, or astrocytes, which have been the favorite targets of gene transfer experiments. This review questions why OLs have been left out of most gene therapy attempts. The first explanation is that the pathogenic role of OLs is still discussed in most CNS diseases. Another reason is that the so-called ubiquitous CAG, CBA, CBh, or CMV promoters—widely used in gene therapy studies—are unable or poorly able to activate the transcription of episomal transgene copies brought by adeno-associated virus (AAV) vectors in OLs. Accordingly, transgene expression in OLs has either not been found or not been evaluated in most gene therapy studies in rodents or non-human primates. The aims of the current review are to give OLs their rightful place among the neural cells that future gene therapy could target and to encourage researchers to test the effect of OL transduction in various CNS diseases.